Amylin Pharmaceuticals, which recently has its lead product Symlin(pramlintide acetate) rejected by a US panel (Marketletter August 6), has reported positive preliminary results from a Phase II dose-escalation study of AC2993 (synthetic exendin-4) as a treatment for type 2 diabetes. A previous Phase II trial demonstrated that AC2993 was an effective treatment for type 2 diabetes and significantly reduced blood glucose concentrations (Marketletter July 9).
During the recent trial, patients were administered with either AC2993 at gradually increasing doses or placebo over 35 days. Both groups were then given AC2993, the control group receiving the target dose with no prior titration. Results demonstrated that treatment with a target dose of AC2993 with a dose titration led to a significant reduction in the incidence of nausea, compared to patients receiving the equivalent target dose without titration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze